

# Shinji Yamazaki

## List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1010964/shinji-yamazaki-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20

papers

331

citations

9

h-index

18

g-index

20

ext. papers

414

ext. citations

4.3

avg, IF

3.57

L-index

#	Paper	IF	Citations
20	Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2021</b> ,	4.5	3
19	SAM Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> ,	6.1	3
18	A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 1412-1422	4.9	1
17	Evaluation of Prediction Accuracy for Volume of Distribution in Rat and Human Using In Vitro, In Vivo, PBPK and QSAR Methods. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 110, 1799-1823	3.9	1
16	Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2021</b> , 10, 1018-1031	4.5	2
15	Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2020</b> , 373, 220-229	4.7	2
14	Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2019</b> , 8, 634-642	4.5	20
13	Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters. <i>Journal of Clinical Pharmacology</i> , <b>2018</b> , 58, 1053-1060 <sup>2</sup>	2.9	
12	Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2018</b> , 433-466	0.4	1
11	Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. <i>Drug Metabolism and Disposition</i> , <b>2018</b> , 46, 1200-1211	4	10
10	Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1080-1090	12.9	17
9	Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 253-65	5.5	8
8	Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 1417-29	4	34
7	Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 54-62	4	20
6	Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2014</b> , 351, 67-76	4.7	23
5	Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. <i>AAPS Journal</i> , <b>2013</b> , 15, 354-66	3.7	40
4	Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 383-93	4	47

## LIST OF PUBLICATIONS

3	Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 937-45	4	2
2	Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 1267-74	4	89
1	Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. <i>Drug Metabolism and Disposition</i> , <b>2004</b> , 32, 398-404	4	6